Loading
A Massachusetts company making CAR-T cell therapy aimed at ICAM-1, a molecule that some solid tumours carry in large amounts. Its first product is being tested in anaplastic thyroid cancer.
AffyImmune describes itself as a clinical-stage company developing affinity-tuned CAR-T cells directed at ICAM-1, engineered so that the cells can be monitored non-invasively during treatment (AffyImmune website). Its lead candidate, AIC100, is an ICAM-1-directed CAR-T therapy developed for anaplastic and advanced differentiated thyroid cancer (AffyImmune website). The company announced on 23 July 2024 that the FDA had granted AIC100 Regenerative Medicine Advanced Therapy (RMAT) designation in recurrent anaplastic thyroid cancer (AffyImmune website, news). It is based at 303 Wyman Street, Waltham, Massachusetts (AffyImmune website).
Shares Anaplastic thyroid cancer, Thyroid cancer.
Shares Anaplastic thyroid cancer, Thyroid cancer.
Shares Anaplastic thyroid cancer, Thyroid cancer.
Shares CAR-T cell therapy and the tag car-t.
Shares CAR-T cell therapy and the tag car-t.
Shares CAR-T cell therapy and the tag car-t.
Shares CAR-T cell therapy and the tag car-t.
Shares Cassian Yee, CAR-T cell therapy.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/